Company · CIK 0000874015 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
IONIS PHARMACEUTICALS INC · IONS
Insider activity reported against this company. All insider holders · Files at: AKCA, RGLS. On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 5, 2015 SForm 4 → | Mar 9, 7:27 pm EDT | Elizabeth L HougenSVP, Finance & CFO | 28,094 | $71.57 | $2,010,823 | 3,387 | −89.2% | plan? |
| Mar 5, 2015 MForm 4 → | Mar 9, 7:27 pm EDT | Elizabeth L HougenSVP, Finance & CFO | 28,094 | $10.50 | $295,065 | 10,824 | — | plan? |
| Mar 5, 2015 SForm 4 → | Mar 9, 7:27 pm EDT | Patrick R. O'NeilSVP, Legal & General Counsel | 5,800 | $71.67 | $415,674 | 6,174 | −48.4% | plan? |
| Mar 5, 2015 MForm 4 → | Mar 9, 7:27 pm EDT | Patrick R. O'NeilSVP, Legal & General Counsel | 5,800 | $9.63 | $55,865 | 10,307 | — | plan? |
| Mar 5, 2015 SForm 4 → | Mar 9, 7:26 pm EDT | Joseph H WenderDirector | 12,500 | $71.61 | $895,174 | 30,217 | −29.3% | plan? |
| Mar 5, 2015 MForm 4 → | Mar 9, 7:26 pm EDT | Joseph H WenderDirector | 12,500 | $9.77 | $122,125 | 42,717 | — | plan? |
| Mar 5, 2015 SForm 4 → | Mar 9, 7:25 pm EDT | Joseph Klein IIIDirector | 7,000 | $70.95 | $496,682 | 4,095 | −63.1% | plan? |
| Mar 5, 2015 MForm 4 → | Mar 9, 7:25 pm EDT | Joseph Klein IIIDirector | 10,000 | $10.18 | $101,800 | 11,095 | — | plan? |
| Mar 2, 2015 SForm 4 → | Mar 4, 7:15 pm EST | Joseph H WenderDirector | 7,000 | $65.97 | $461,785 | 30,217 | −18.8% | plan? |
| Feb 12, 2015 SForm 4 → | Feb 17, 5:39 pm EST | Joseph H WenderDirector | 10,000 | $62.15 | $621,460 | 37,217 | −21.2% | plan? |
| Feb 12, 2015 MForm 4 → | Feb 17, 5:39 pm EST | Joseph H WenderDirector | 10,000 | $3.95 | $39,500 | 47,217 | — | plan? |
| Feb 11, 2015 GForm 4 → | Feb 13, 5:50 pm EST | Joseph Klein IIIDirector | 2,000 | — | — | 1,095 | — | plan? |
| Feb 3, 2015 MForm 4 → | Feb 5, 6:08 pm EST | Joseph LoscalzoDirector | 938 | — | — | 938 | — | plan? |
| Jan 27, 2015 SForm 4 → | Jan 29, 7:03 pm EST | Stanley T CrookeChairman and CEO, Director | 11,000 | $72.93 | $802,186 | 1,297 | −89.5% | plan? |
| Jan 27, 2015 MForm 4 → | Jan 29, 7:03 pm EST | Stanley T CrookeChairman and CEO, Director | 11,000 | $11.08 | $121,920 | 2,297 | — | plan? |
| Jan 16, 2015 SForm 4 → | Jan 20, 8:00 pm EST | Stanley T CrookeChairman and CEO, Director | 9,054 | $67.96 | $615,348 | 1,297 | −87.5% | plan? |
| Jan 16, 2015 SForm 4 → | Jan 20, 7:58 pm EST | B Lynne ParshallCOO & Secretary, Director | 4,093 | $67.96 | $278,177 | 8,072 | −33.6% | plan? |
| Jan 16, 2015 SForm 4 → | Jan 20, 7:57 pm EST | Brett P MoniaSVP, Antisense Drug Discovery | 1,534 | $67.96 | $104,257 | 4,426 | −25.7% | plan? |
| Jan 16, 2015 SForm 4 → | Jan 20, 7:57 pm EST | Elizabeth L HougenSVP, Finance & CFO | 1,291 | $67.96 | $87,742 | 3,387 | −27.6% | plan? |
| Jan 16, 2015 SForm 4 → | Jan 20, 7:56 pm EST | Patrick R. O'NeilSVP, Legal & General Counsel | 1,291 | $67.96 | $87,742 | 6,174 | −17.3% | plan? |
| Jan 16, 2015 SForm 4 → | Jan 20, 7:55 pm EST | C Frank BennettSVP, Antisense Research | 1,518 | $67.96 | $103,169 | 7,229 | −17.4% | plan? |
| Jan 16, 2015 SForm 4 → | Jan 20, 7:53 pm EST | Richard S GearySVP, Development | 1,543 | $67.96 | $104,868 | 7,570 | −16.9% | plan? |
| Jan 15, 2015 MForm 4 → | Jan 20, 8:00 pm EST | Stanley T CrookeChairman and CEO, Director | 17,425 | — | — | 1,433 | — | plan? |
| Jan 15, 2015 MForm 4 → | Jan 20, 7:58 pm EST | B Lynne ParshallCOO & Secretary, Director | 7,748 | — | — | 9,890 | — | plan? |
| Jan 15, 2015 MForm 4 → | Jan 20, 7:57 pm EST | Brett P MoniaSVP, Antisense Drug Discovery | 4,025 | — | — | 5,140 | — | plan? |
| Jan 15, 2015 MForm 4 → | Jan 20, 7:57 pm EST | Elizabeth L HougenSVP, Finance & CFO | 3,383 | — | — | 4,101 | — | plan? |
| Jan 15, 2015 MForm 4 → | Jan 20, 7:56 pm EST | Patrick R. O'NeilSVP, Legal & General Counsel | 3,383 | — | — | 6,888 | — | plan? |
| Jan 15, 2015 MForm 4 → | Jan 20, 7:55 pm EST | C Frank BennettSVP, Antisense Research | 3,984 | — | — | 7,943 | — | plan? |
| Jan 15, 2015 MForm 4 → | Jan 20, 7:53 pm EST | Richard S GearySVP, Development | 4,049 | — | — | 8,284 | — | plan? |
| Jan 12, 2015 SForm 4 → | Jan 13, 6:49 pm EST | Richard S GearySVP, Development | 597 | $73.10 | $43,641 | 5,064 | −10.5% | plan? |
| Jan 9, 2015 SForm 4 → | Jan 13, 6:51 pm EST | Stanley T CrookeChairman and CEO, Director | 11,000 | $73.57 | $809,270 | 627 | −94.6% | plan? |
| Jan 9, 2015 MForm 4 → | Jan 13, 6:51 pm EST | Stanley T CrookeChairman and CEO, Director | 11,000 | $11.08 | $121,920 | 1,627 | — | plan? |
| Jan 6, 2015 SForm 4 → | Jan 8, 7:15 pm EST | Stanley T CrookeChairman and CEO, Director | 22,000 | $67.04 | $1,474,946 | 627 | −97.2% | plan? |
| Jan 6, 2015 MForm 4 → | Jan 8, 7:15 pm EST | Stanley T CrookeChairman and CEO, Director | 22,000 | $11.08 | $243,840 | 1,627 | — | plan? |
| Jan 2, 2015 SForm 4 → | Jan 5, 8:04 pm EST | B Lynne ParshallCOO & Secretary, Director | 11,200 | $62.12 | $695,688 | 4,417 | −71.7% | plan? |
| Jan 2, 2015 SForm 4 → | Jan 5, 8:03 pm EST | Patrick R. O'NeilSVP, Legal & General Counsel | 1,500 | $62.12 | $93,173 | 4,082 | −26.9% | plan? |
| Jan 2, 2015 SForm 4 → | Jan 5, 7:56 pm EST | Brett P MoniaSVP, Antisense Drug Discovery | 76 | $62.75 | $4,769 | 1,935 | −3.78% | plan? |
| Jan 1, 2015 JMForm 4 → | Jan 5, 8:04 pm EST | B Lynne ParshallCOO & Secretary, Director | 11,311 | $14.84 | $167,863 | 15,617 | — | plan? |
| Jan 1, 2015 JMForm 4 → | Jan 5, 8:03 pm EST | Patrick R. O'NeilSVP, Legal & General Counsel | 1,829 | $13.73 | $25,105 | 4,365 | — | plan? |
| Jan 1, 2015 JForm 4 → | Jan 5, 8:01 pm EST | Elizabeth L HougenSVP, Finance & CFO | 63 | $30.05 | $1,893 | 1,295 | — | plan? |
| Jan 1, 2015 JForm 4 → | Jan 5, 7:59 pm EST | C Frank BennettSVP, Antisense Research | 136 | $30.05 | $4,086 | 4,763 | — | plan? |
| Jan 1, 2015 JForm 4 → | Jan 5, 7:57 pm EST | Richard S GearySVP, Development | 273 | $30.05 | $8,203 | 5,661 | — | plan? |
| Jan 1, 2015 JForm 4 → | Jan 5, 7:56 pm EST | Brett P MoniaSVP, Antisense Drug Discovery | 198 | $30.05 | $5,949 | 2,011 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2015 MForm 4 → | Dec 17, 7:23 pm EST | C Frank BennettSVP, Antisense Research | 7,909 | — | — | 0 | — | |
| Dec 1, 2015 MForm 4 → | Dec 2, 6:49 pm EST | Patrick R. O'NeilSVP, Legal & General Counsel | 1,000 | — | — | 2,067 | — | |
| Nov 11, 2015 MForm 4 → | Nov 12, 7:02 pm EST | Joseph Klein IIIDirector | 6,875 | — | — | 2,812 | — | |
| Nov 10, 2015 MForm 4 → | Nov 12, 7:03 pm EST | C Frank BennettSVP, Antisense Research | 5,000 | — | — | 7,909 | — | |
| Nov 9, 2015 GForm 4 → | Nov 9, 7:45 pm EST | B Lynne ParshallCOO & Secretary, Director | 8,000 | — | — | 1,000 | — | |
| Nov 6, 2015 MForm 4 → | Nov 9, 7:28 pm EST | C Frank BennettSVP, Antisense Research | 5,000 | — | — | 12,909 | — | |
| Nov 3, 2015 MForm 4 → | Nov 4, 7:00 pm EST | Patrick R. O'NeilSVP, Legal & General Counsel | 1,000 | — | — | 3,067 | — | |
| Oct 21, 2015 MForm 4 → | Oct 23, 7:35 pm EDT | Stanley T CrookeChairman and CEO, Director | 44,000 | — | — | 2,000 | — | |
| Oct 1, 2015 MForm 4 → | Oct 5, 7:14 pm EDT | B Lynne ParshallCOO & Secretary, Director | 12,436 | — | — | 29,354 | — | |
| Jul 6, 2015 MForm 4 → | Jul 8, 5:55 pm EDT | B Lynne ParshallCOO & Secretary, Director | 6,218 | — | — | 17,027 | — | |
| Jul 6, 2015 MForm 4 → | Jul 8, 5:54 pm EDT | Stanley T CrookeChairman and CEO, Director | 6,175 | — | — | 5,000 | — | |
| Jul 1, 2015 MForm 4 → | Jul 2, 6:06 pm EDT | B Lynne ParshallCOO & Secretary, Director | 6,218 | — | — | 1,375 | — | |
| Jul 1, 2015 MForm 4 → | Jul 2, 6:02 pm EDT | Stanley T CrookeChairman and CEO, Director | 6,175 | — | — | 6,175 | — | |
| Jul 1, 2015 AMForm 4 → | Jul 2, 6:00 pm EDT | Joseph H WenderDirector | 20,115 | — | — | 16,000 | — | |
| Jul 1, 2015 AMForm 4 → | Jul 2, 6:00 pm EDT | Frederick T MutoDirector | 20,115 | — | — | 16,000 | — | |
| Jul 1, 2015 AMForm 4 → | Jul 2, 5:59 pm EDT | Joseph LoscalzoDirector | 19,334 | — | — | 16,000 | — | |
| Jul 1, 2015 AMForm 4 → | Jul 2, 5:58 pm EDT | Joseph Klein IIIDirector | 20,115 | — | — | 16,000 | — | |
| Jul 1, 2015 AMForm 4 → | Jul 2, 5:57 pm EDT | Breaux CastlemanDirector | 20,741 | — | — | 16,000 | — | |
| Jul 1, 2015 AMForm 4 → | Jul 2, 5:57 pm EDT | Spencer R BerthelsenDirector | 20,115 | — | — | 16,000 | — | |
| Jun 8, 2015 MForm 4 → | Jun 10, 6:36 pm EDT | Brett P MoniaSVP, Antisense Drug Discovery | 7,600 | — | — | 0 | — | |
| Jun 1, 2015 MForm 4 → | Jun 3, 5:29 pm EDT | Frederick T MutoDirector | 10,000 | — | — | 0 | — | |
| Apr 17, 2015 MForm 4 → | Apr 17, 6:13 pm EDT | Spencer R BerthelsenDirector | 10,000 | — | — | 0 | — | |
| Apr 7, 2015 MForm 4 → | Apr 8, 5:12 pm EDT | B Lynne ParshallCOO & Secretary, Director | 5,565 | — | — | 37,628 | — | |
| Apr 7, 2015 MForm 4 → | Apr 8, 5:11 pm EDT | Stanley T CrookeChairman and CEO, Director | 22,377 | — | — | 7,350 | — | |
| Apr 1, 2015 MForm 4 → | Apr 6, 11:51 am EDT | B Lynne ParshallCOO & Secretary, Director | 5,377 | — | — | 43,193 | — | |
| Apr 1, 2015 MForm 4 → | Apr 6, 11:50 am EDT | Stanley T CrookeChairman and CEO, Director | 21,623 | — | — | 9,384 | — | |
| Mar 23, 2015 MForm 4 → | Mar 25, 4:23 pm EDT | C Frank BennettSVP, Antisense Research | 15,000 | — | — | 17,909 | — | |
| Mar 19, 2015 MForm 4 → | Mar 20, 6:58 pm EDT | Elizabeth L HougenSVP, Finance & CFO | 10,000 | — | — | 10,000 | — | |
| Mar 19, 2015 MForm 4 → | Mar 20, 6:56 pm EDT | Richard S GearySVP, Development | 8,000 | — | — | 17,240 | — | |
| Mar 19, 2015 MForm 4 → | Mar 20, 6:55 pm EDT | Patrick R. O'NeilSVP, Legal & General Counsel | 30,525 | — | — | 31,875 | — | |
| Mar 18, 2015 MForm 4 → | Mar 20, 6:57 pm EDT | Joseph H WenderDirector | 12,500 | — | — | 0 | — | |
| Mar 5, 2015 MForm 4 → | Mar 9, 7:45 pm EDT | Richard S GearySVP, Development | 15,080 | — | — | 7,035 | — | |
| Mar 5, 2015 MForm 4 → | Mar 9, 7:27 pm EDT | Elizabeth L HougenSVP, Finance & CFO | 28,094 | — | — | 4,063 | — | |
| Mar 5, 2015 MForm 4 → | Mar 9, 7:27 pm EDT | Patrick R. O'NeilSVP, Legal & General Counsel | 5,800 | — | — | 1,617 | — | |
| Mar 5, 2015 MForm 4 → | Mar 9, 7:26 pm EDT | Joseph H WenderDirector | 12,500 | — | — | 0 | — | |
| Mar 5, 2015 MForm 4 → | Mar 9, 7:25 pm EDT | Joseph Klein IIIDirector | 10,000 | — | — | 5,937 | — | |
| Feb 12, 2015 MForm 4 → | Feb 17, 5:39 pm EST | Joseph H WenderDirector | 10,000 | — | — | 0 | — | |
| Feb 3, 2015 MForm 4 → | Feb 5, 6:08 pm EST | Joseph LoscalzoDirector | 938 | — | — | 2,812 | — | |
| Jan 27, 2015 MForm 4 → | Jan 29, 7:03 pm EST | Stanley T CrookeChairman and CEO, Director | 11,000 | — | — | 11,350 | — | |
| Jan 15, 2015 AMForm 4 → | Jan 20, 8:00 pm EST | Stanley T CrookeChairman and CEO, Director | 46,375 | — | — | 1,062 | — | |
| Jan 15, 2015 AForm 4 → | Jan 20, 7:59 pm EST | Sarah BoyceChief Business Officer | 8,750 | — | — | 8,750 | — | |
| Jan 15, 2015 AMForm 4 → | Jan 20, 7:58 pm EST | B Lynne ParshallCOO & Secretary, Director | 29,824 | — | — | 10,312 | — | |
| Jan 15, 2015 AMForm 4 → | Jan 20, 7:57 pm EST | Brett P MoniaSVP, Antisense Drug Discovery | 10,095 | — | — | 5,625 | — | |
| Jan 15, 2015 AMForm 4 → | Jan 20, 7:57 pm EST | Elizabeth L HougenSVP, Finance & CFO | 8,901 | — | — | 5,625 | — | |
| Jan 15, 2015 AMForm 4 → | Jan 20, 7:56 pm EST | Patrick R. O'NeilSVP, Legal & General Counsel | 8,625 | — | — | 5,625 | — | |
| Jan 15, 2015 AMForm 4 → | Jan 20, 7:55 pm EST | C Frank BennettSVP, Antisense Research | 9,226 | — | — | 5,625 | — | |
| Jan 15, 2015 AMForm 4 → | Jan 20, 7:53 pm EST | Richard S GearySVP, Development | 9,567 | — | — | 5,625 | — | |
| Jan 9, 2015 MForm 4 → | Jan 13, 6:51 pm EST | Stanley T CrookeChairman and CEO, Director | 11,000 | — | — | 12,350 | — | |
| Jan 6, 2015 MForm 4 → | Jan 8, 7:15 pm EST | Stanley T CrookeChairman and CEO, Director | 22,000 | — | — | 13,350 | — | |
| Jan 2, 2015 AMForm 4 → | Jan 5, 8:04 pm EST | B Lynne ParshallCOO & Secretary, Director | 143,658 | — | — | 48,570 | — | |
| Jan 2, 2015 AMForm 4 → | Jan 5, 8:03 pm EST | Patrick R. O'NeilSVP, Legal & General Counsel | 32,957 | — | — | 9,750 | — | |
| Jan 2, 2015 AMForm 4 → | Jan 5, 8:02 pm EST | Stanley T CrookeChairman and CEO, Director | 173,700 | — | — | 8,700 | — | |
| Jan 2, 2015 AForm 4 → | Jan 5, 8:01 pm EST | Elizabeth L HougenSVP, Finance & CFO | 33,112 | — | — | 33,112 | — | |
| Jan 2, 2015 AForm 4 → | Jan 5, 7:59 pm EST | C Frank BennettSVP, Antisense Research | 31,457 | — | — | 31,457 | — | |
| Jan 2, 2015 AForm 4 → | Jan 5, 7:57 pm EST | Richard S GearySVP, Development | 33,112 | — | — | 33,112 | — | |
| Jan 2, 2015 AForm 4 → | Jan 5, 7:56 pm EST | Brett P MoniaSVP, Antisense Drug Discovery | 36,423 | — | — | 36,423 | — | |
| Jan 1, 2015 AForm 4 → | Jan 5, 8:31 pm EST | Sarah BoyceChief Business Officer | 52,500 | — | — | 52,500 | — |
Filed by this entity as an insider elsewhere — common stock
| Trade | Reported (ET) | Company | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 17, 2018 JForm 4 → | Oct 18, 8:05 pm EDT | AKCEA THERAPEUTICS, INC.AKCA | 1,671,849 | — | — | 67,383,965 | — | plan? |
| Aug 3, 2018 JForm 4 → | Aug 6, 5:17 pm EDT | AKCEA THERAPEUTICS, INC.AKCA | 1,597,571 | — | — | 65,712,116 | — | plan? |
| Apr 17, 2018 PForm 4 → | Apr 19, 6:48 pm EDT | AKCEA THERAPEUTICS, INC.AKCA | 10,666,666 | $18.75 | $199,999,988 | 64,114,545 | +20.0% | plan? |
| Apr 17, 2018 JForm 4 → | Apr 19, 6:48 pm EDT | AKCEA THERAPEUTICS, INC.AKCA | 8,000,000 | — | — | 53,447,879 | — | plan? |
| Jul 19, 2017 PForm 4 → | Jul 21, 4:04 pm EDT | AKCEA THERAPEUTICS, INC.AKCA | 3,125,000 | $8.00 | $25,000,000 | 45,447,879 | +7.38% | plan? |
| Jul 19, 2017 CJForm 4 → | Jul 21, 4:04 pm EDT | AKCEA THERAPEUTICS, INC.AKCA | 42,322,879 | — | — | 42,322,879 | — | plan? |
| Jul 15, 2015 SForm 4 → | Jul 17, 6:08 pm EDT | Regulus Therapeutics Inc.RGLS | 343,133 | $10.60 | $3,636,078 | 5,173,172 | −6.22% | plan? |
| Jun 30, 2015 SForm 4 → | Jul 2, 4:28 pm EDT | Regulus Therapeutics Inc.RGLS | 13,248 | $10.79 | $143,010 | 5,516,305 | −0.24% | plan? |
| Jun 23, 2015 GForm 4 → | Jul 2, 4:28 pm EDT | Regulus Therapeutics Inc.RGLS | 13,248 | — | — | 5,529,553 | — | plan? late |
Filed by this entity as an insider elsewhere — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Company | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 19, 2017 CForm 4 → | Jul 21, 4:04 pm EDT | AKCEA THERAPEUTICS, INC.AKCA | 28,884,540 | — | — | 0 | — |